<DOC>
	<DOCNO>NCT00997204</DOCNO>
	<brief_summary>This study conduct explore clinical safety , local tolerability , convenience effectiveness self-treatment hereditary angioedema ( HAE ) attack subcutaneous injection icatibant .</brief_summary>
	<brief_title>EASSI - Evaluation Safety Self-Administration With Icatibant</brief_title>
	<detailed_description>This Phase IIIb study multi-center open-label single dose level . Subjects document diagnosis HAE Type I II eligible participate trial . Eligible subject include received treatment HAE icatibant previous clinical trial , subject previously treat marketed product Firazyr® subject naïve icatibant treatment . All subject train method self-administration enrollment visit ( Visit 1 ) .For training session , syringe pre-filled 3 mL placebo solution use place icatibant . Comprehensive educational material instruction include pictograms develop subject illustrate method self-administration use Patient Diary . The training material provide additional information self-diagnose HAE attack decide necessity treat.In addition , instruction provide case laryngeal attack .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Icatibant</mesh_term>
	<mesh_term>Bradykinin</mesh_term>
	<criteria>Each patient must meet follow criterion enrol study . 1 . Males females 18 year age time inform consent 2 . Documented diagnosis HAE Type I II base ALL follow criterion : Family and/or medical history Characteristic attack manifestation , recurrent attack Historical functional C1INH &lt; 50 % normal value 3 . Women childbearing potential must use consistently correctly highly effective , adequate method birth control ( failure rate le 1 % per year ) sexual abstinence vasectomise partner duration study . Hormonal contraception continue verified physician n't affect course HAE attack . 4 . Mental physical condition allow patient complete baseline assessment , selfadminister icatibant follow study procedure . 5 . Ability provide sign write informed consent aspect study explain discussed patient . Patients meet follow criterion exclude study . 1 . Participation clinical trial another investigational medicinal product within past month ( except previous icatibant study ) . 2 . Diagnosis angioedema Type I Type II HAE . 3 . Evidence symptomatic coronary artery disease base medical history , particular , unstable angina pectoris severe coronary heart disease . 4 . Congestive heart failure ( NYHA Class 3 4 ) . 5 . Stroke within past 6 month . 6 . Treatment angiotensin convert enzyme ( ACE ) inhibitor . 7 . Pregnancy and/or breastfeed . 8 . In opinion investigator : mental condition render patient unable understand nature , scope possible consequence study . 9 . In opinion investigator : unlikely comply protocol , example , uncooperative attitude , inability return followup visit , unlikely complete study reason . 10 . In opinion investigator : inability manage study medication selfadministration injection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HAE</keyword>
	<keyword>Type I HAE</keyword>
	<keyword>Type II HAE</keyword>
</DOC>